Related Experiment Videos
Tividenofusp Alfa: First Approval
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. mdt@adis.com.
Molecular Diagnosis & Therapy
|June 18, 2026
Summary
Tividenofusp alfa, a novel enzyme replacement therapy, shows promise for treating Hunter syndrome (MPS II). Its development led to accelerated US approval for neurologic manifestations in pediatric patients.
Area of Science:
- Biotechnology and Enzyme Replacement Therapy
- Lysosomal Storage Diseases
- Neurology
Background:
- Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare X-linked recessive lysosomal storage disease.
- It results from iduronate-2-sulfatase deficiency, leading to glycosaminoglycan accumulation.
- Current treatments are limited, especially for central nervous system manifestations.
Purpose of the Study:
- To summarize the development milestones of tividenofusp alfa for MPS II.
- To highlight the clinical data supporting its accelerated approval.
- To provide an overview of its novel mechanism for CNS penetration.
Main Methods:
- Development of tividenofusp alfa, an enzyme fused to a transferrin receptor-binding Fc domain.
- Phase I/II clinical trial evaluating safety, tolerability, and efficacy.
- Assessment of cerebrospinal fluid heparan sulphate levels as a biomarker.
Main Results:
- Tividenofusp alfa demonstrated reduction in cerebrospinal fluid heparan sulphate levels in MPS II patients.
- Accelerated approval granted in the USA in March 2026 for neurologic manifestations.
- Priority Medicine designation received from the European Medicines Agency.
Conclusions:
- Tividenofusp alfa represents a significant advancement in MPS II treatment, particularly for neurologic aspects.
- Its brain-penetrant design facilitates enzyme delivery to both CNS and peripheral tissues.
- Continued approval is contingent on confirmatory trial results verifying clinical benefit.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...